Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Buy" by Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have earned a consensus rating of "Buy" from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $20.20.

Several analysts recently commented on ALT shares. HC Wainwright reaffirmed a "buy" rating and set a $12.00 target price on shares of Altimmune in a report on Thursday, April 3rd. William Blair reaffirmed a "market perform" rating on shares of Altimmune in a report on Friday, March 14th. Finally, Wall Street Zen raised shares of Altimmune from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd.

Insiders Place Their Bets

In other news, CFO Gregory L. Weaver bought 10,000 shares of the company's stock in a transaction dated Thursday, March 13th. The stock was bought at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the transaction, the chief financial officer now owns 10,000 shares of the company's stock, valued at $52,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.10% of the company's stock.

Hedge Funds Weigh In On Altimmune

Several hedge funds and other institutional investors have recently made changes to their positions in the company. SBI Securities Co. Ltd. bought a new stake in shares of Altimmune during the 4th quarter valued at approximately $45,000. Steward Partners Investment Advisory LLC boosted its stake in shares of Altimmune by 38.9% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 28,050 shares of the company's stock valued at $202,000 after purchasing an additional 7,850 shares during the last quarter. Cullen Frost Bankers Inc. acquired a new position in shares of Altimmune during the 4th quarter valued at $72,000. Raymond James Financial Inc. acquired a new position in shares of Altimmune during the 4th quarter valued at $88,000. Finally, Sequoia Financial Advisors LLC lifted its position in shares of Altimmune by 34.5% during the 4th quarter. Sequoia Financial Advisors LLC now owns 13,655 shares of the company's stock valued at $98,000 after acquiring an additional 3,500 shares during the period. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Stock Down 0.5%

Shares of ALT stock opened at $5.46 on Friday. The firm has a fifty day moving average of $5.09 and a 200-day moving average of $6.37. Altimmune has a 12-month low of $3.55 and a 12-month high of $11.16. The company has a market capitalization of $442.84 million, a price-to-earnings ratio of -3.52 and a beta of 1.13.

Altimmune (NASDAQ:ALT - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.09. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter last year, the firm earned ($0.34) earnings per share. On average, equities analysts expect that Altimmune will post -1.35 EPS for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.